Dexmedetomidine (Igalmi)
Small molecule
Also known as BXCL501
Evidence outlook
Approved: the acute treatment of agitation associated with schizophrenia or bipolar I or II... (FDA)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also in development:Bipolar Disorder · Phase 3Alzheimer's Disease Agitation
Also approved (1)
- IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SERENITY I NCT04268303 · Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders This was a randomized, quadruple-masked, placebo-controlled trial involving 380 participants. The primary clinical endpoint, change in the Positive and Negative Syndrome Scale–Excited Component score at 2 hours, was statistically significantly better with both dexmedetomidine doses than with placebo. Registry: NCT04268303 | 3 | Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours) 2020-05-06 | Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69) | Reliable signal | link ↗ |
View 1 more trial
SERENITY III NCT05658510 · Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders The study randomized 452 participants to dexmedetomidine or placebo and used quadruple masking, including blinded participants, clinicians, investigators, and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Label revised to mixed on 2026-09-02: the Part 1 efficacy primary was not met (p=0.077) while the Part 2 safety primary was reported met. Two registered primary endpoints: Part 1 efficacy (PEC change at 2 hours) p=0.077, not statistically significant; Part 2 at-home safety primary (SAE/TEAE incidence vs placebo) reported met by the sponsor on 2025-08-27. A met safety primary carries no efficacy evidence. Registry: NCT05658510 | 3 | Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score (2 hours); Part 2: The incidence of SAEs and TEAEs compared with placebo. (Through study completion, an average of 12 weeks) 2025-08-15 | Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Alzheimer's Disease Agitation: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dexmedetomidine (Igalmi): this drug | Stage not on record | Small molecule | Alpha-2 adrenergic receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA, Dopamine/norepinephrine transporter | Reliable signal | NCT05557409: Change in CMAI total score, baseline to Week 5 (ADVANCE-2): -13.8 points AXS-05 vs -12.6 points placebo; did not reach statistical significance missed NCT03226522: Change in CMAI Total Score (5 weeks): AXS-05 -15.4 score on a scale (Standard Error 1.25) vs Bupropion -10 score on a scale (Standard Error 3.02) vs Placebo -11.5 score on a scale (Standard Error 1.1) | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dexmedetomidine (Igalmi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent